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“A STUDY ON VITAMIN-D LEVEL AND GLYCEMIC STATUS 
IN ACUTE ISCHEMIC STROKE AND THEIR IMPACT” 
 
ABSTRACT: 
Stroke remains to be one of the leading causes of the mortality worldwide. The majority 
of the stroke as a result of occlusion of the blood supply to the brain leading to cerebral 
infarction (Ischemic stroke). The Vitamin D deficiency is present worldwide, and recent studies 
found that there is direct correlation between Vitamin D deficiency and ischemic stroke.  
          The hyperglycemia on admission is associated with poor outcome in the patient with 
ischemic stroke. The hyperglycemia is associated poor salvage of the ischemic penumbra. The 
hyperglycemic ischemic stroke patient are associated with higher infarct volume on admission, a 
greater progression of the ischemic stroke, resulting in higher final infarct volume when 
compared with the patient who are euglycemia on admission.  
          In this study, ischemic stroke patients fitting into the criteria are selected, and the Vitamin 
D are assessed, the glycemic status on admission is correlated with the infarct volume on 
admission and on 3rd to 7th day of the stroke by using MRI-Diffusion weighted images of the 
brain.  
Conclusion:  
In our study the results are  Vitamin D deficiency common in ischemic stroke, and the 
hyperglycemia on admission is associated with higher infarct volume on admission, a greater 
progression of the ischemic stroke, resulting in higher final infarct volume when compared with 
the patient who are euglycemia on admission.   
 
KEY WORS: 
ischemic stroke, infarct volume, hyperglycemia, Vitamin D, MRI-Diffusion weighted 
image, ischemic penumbra 
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INTRODUCTION 
 
Stroke remains to be the one of the leading cause of death in the world, 
although the incidence of the stroke seems to be decreasing because of the 
advances in the management and availability of preventive measures. 
Ischemic stroke contributes for the larger number of stroke cases, in which, 
the partial or complete occlusion of the regional vasculature of the brain 
leading on to the infarction of the brain tissue.                         
Vitamin D, actually a pro-hormone, is synthesized in the human body, 
in the presence of sunlight (UV–B).The current lifestyle of reduced exposure 
to the sunlight leads increased risk for the development of Vitamin D 
deficiency worldwide.                        
Vitamin D is required for the calcium homeostasis, other functions 
including role in muscle contraction, immune functions, nerve conduction. 
Vitamin D deficiency is at risk for the development of various neurological 
diseases like dementia, Alzheimer diseases,  multiple sclerosis, stroke. 
Its functions include decreasing renin- angiotensin-aldosterone activity, 
anti- inflammatory, anti-atherosclerotic action, decreasing vascular 
calcification. Other role includes decreasing the protein excretion in the urine, 
role in neuro-protection by insulin like growth factor-1 synthesis. Vitamin D 
2 
 
deficiency leads to systemic hypertension and increases in the stroke 
incidence. 
Acute hyperglycemic response to stress has been recognized since 
Claude Bernard’s observations more than a century ago.1 Stress 
hyperglycemia or in hospital hyperglycemia is present any blood glucose 
valve >140 mg/dl. The mechanism responsible for stress hyperglycemia 
includes stimulation of HPA axis during to the stress for the stroke event. 
This leads onto increased cathecolamines, cortisol, glycogen, resulting in 
increased lipolysis, proteolysis, glycogenolysis, gluconeogenesis. 
Hyperglycemia is associated with abnormal immune function, hemodynamic, 
electromyocardial disturbances and increased infection rate.2 
Regardless of the time period between the stroke and glucose 
estimation, elevated blood sugar levels is common in the ischemic stroke, 
irrespective of the diabetic status. Admission hyperglycemia usually 
correlates with increased infarct size on admission and poor clinical outcome. 
 This study is to assess the vitamin D levels in patients admitting for ischemic 
stroke and to look for Vitamin D level in these group of populations, to find 
correlation between glycemic status and stroke extent / territory during 
admission and hospital stay (3 to7th day) by using multimodal CT/ MRI 
Brain scans. 
 
 
  
 
 
 
AIM AND OBJECTIVES 
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AIMS AND OBJECTIVES 
 
• To study the Vitamin D levels in the ischemic stroke. 
 
• To assess the relation between glycemic status and ischemic stroke 
infarct volume and their territory during admission & course of stay in 
the hospital  ( 3 to 7th day)  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
REVIEW OF LITERATURE 
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REVIEW OF LITERATURE 
 
                Several centuries before Hippocrates mentioned in his description 
of stroke as an apoplexy which means – “thunder struck or sudden depriving 
of one’s sense”. He mentioned that people of ages between forty to sixty or 
more at risk when compared to fellow person. Galen (131- 201 AD), based 
on dissections of animals, was the first person to described the structure of 
brain, its anatomy and its blood supply.  
 
Johann Jacob Wepfer (1620- 1695) described that the sudden onset of 
this apoplexy is due to the blood vessel diseases of brain where in the blood 
supply to the brain (carotid and the vertebral arteries) are affected. He 
showed apart from occlusion of these vessels, bleeding from these vessels 
into the brain was an important cause of apoplexy. 
 
 Thomas Wills, a neuro-anatomist proposed the cerebral blood vessel 
anastomoses at the base of brain(CEREBRAL ANASTOME), and named 
after him – CIRCLE OF WILLIS. He also described transient ischemic 
attacks, existence of occlusion of carotid artery, the embolus as etiology for 
the stroke. 
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John Abercrombie published paper on the apoplexy in that he stated 
headache, stupor, paralysis as the features of apoplexy. Following this, 
several studied had been done and different stroke syndrome established, and 
during twentieth century, there was several advanced technology allowed 
better visualization of the brain anatomy and there functions, and 
pathological lesions affecting the brain. 
 
                Moniz (1874-1955), Portugal neurosurgeon, surgically exposed & 
ligated the cranial artery in the neck, then 30% sodium iodide injected and 
skull films taken at regular intervals. Seldinger, from Sweden, devised 
technique of modern angiography, in which small catheter introduced into 
artery over a flexible guide wire after withdrawing the needle.  
 
In 1960, Hounsfield from Britain, originated the concept of Computed 
Tomography (CT). In the mid 1980, MRI proved superior to CT in picking 
up the old hemosiderin containing hemorrhages, vascular malformation, 
lesion involving posterior cranial fossa, lesion abutting on bony surfaces. 
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Franklin, in early 1961, demonstrated the uses of ultrasound in imaging 
the extra cranial carotid vessels. At the end of 20th century, advanced imaging 
with CT, MRI spectroscopy helped in the localisations, severity and potential 
reversibility of brain ischemia. Vascular lesions can be assessed better by 
using CT and MR angiography.3,4These advances will help in the better 
management of the stroke in upcoming future. 
 
BLOOD SUPPLY OF BRAIN: 
Blood supply for the brain is from two internal carotid artery & two 
vertebral artery. At the base of brain, these blood vessels anastomosis 
forming circle of WILLIS. Of the total weight of body, brain contributes for 
about 2%. Of the total cardiac output, around 20% of the blood enters the 
brain.  
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CIRCLE OF WILLIS 
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MAIN BLOOD SUPPLY TO BRAIN: 
1. Internal carotid artery (Right & Left) 
2. Vertebral artery (Right & Left) 
Circle of Willis: is formed anteriorly by two ACA, which is connected by 
anterior communicating artery anteriorly, posteriorly by two PCA, 
communicating with  anterior circulation by the posterior communicating 
artery. 
 
INTERNAL CAROTID ARTERY (ICA): 
- The internal carotid artery arises from common carotid artery, which 
in turn arises from brachiocephalic artery on right side & aortic arch 
on the left side. 
- Internal carotid artery start at thyroid cartilage level, runs into neck 
without branching, enters into base of the skull through the foramen 
lacerum. Then it enter into cavernous sinus, then comes out of the 
cavernous sinus just medial to the anterior clinoid process. 
- The branches includes –  
• ophthalmic artery,  
• posterior communicating artery,  
• anterior choroidal artery,  
• anterior cerebral artery,  
• middle cerebral artery. 
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- Ophthalmic artery is the first branch arising from internal carotid 
artery, supplies eye and other structures of the orbit.  
- Posterior communicating artery is the next branch of ICA, which runs 
back to join the posterior cerebral artery, supplying optic chiasma, 
optic tract, hypothalamus, midbrain, thalamus. 
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- Anterior choroidal artery arises from distal region of ICA supplying 
the internal capsule, optic tract, basal ganglia, thalamus, lateral 
geniculate body, midbrain, proximal optic radiation. 
- Middle cerebral artery enters sylvian fissure, before entering it gives 
of deep cerebral branches (Lenticulostriate branches). In the sylvian 
fissure, the MCA divides into superior & inferior division supplying 
the lateral part of the cerebral cortex. The lenticulostriate branches 
supply the putamen, outer globus pallidus, internal capsule (posterior 
limb). 
- Vertebral artery arises from the proximal subclavian artery, then it 
ascends upward reaching the transverse foramina of sixth & second 
vertebrae, then it join with the vertebral artery of the other side to 
form basiliar artery. The branches of vertebral artery includes – 
anterior spinal artery, posterior spinal artery, posterior inferior 
cerebellar artery, small penetrating branches to medulla. The posterior 
inferior cerebellar artery supplies inferior vermis, inferior and 
posterior surfaces of the cerebellum, brainstem. 
- Basilar artery ascends up to the pons & in the inter-peduncular cistern 
where it divide into posterior cerebral artery. The other branches 
include labyrinthine artery; anterior inferior cerebellar artery which 
supply the rostral cerebellum, brainstem, inner ear; the  superior 
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cerebellar artery supplying the brainstem, cerebellar hemisphere 
(superior part),vermis, dentate nucleus;  the posterior cerebral artery. 
- The posterior cerebral artery winds rounds the midbrain near the 
occulomotor nerve, and supplies temporal lobe (inferior part), 
occipital lobe. The deep branches of the PCA supply mainly midbrain, 
thalamus, hypothalamus, geniculate bodies ( thalamostriate branches). 
The common variation of the posterior cerebral artery is the in about 
15% people, PCA is the direct continuation of the posterior 
communicating artery (PCoM). 
 
COLLATERAL BLOOD SUPPLY IN THE BRAIN: 
In the normal situation, the anterior two-third of the cerebral 
circulation is supplie by the internal carotid artery and the posterior one – 
third is supplied by the vertebral artery. In the cases of blood vessels 
occlusion, collateral develop distal to the site of occlusion, and the collateral 
development depends on the vessels occluded, and whether the other artery 
are free of disease or not.   
 
Other regions of collateral blood flow are: 
1. Leptomeningeal anastomoses 
2. Around the orbit  
3. Parenchymal anastomes 
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Venous drainage of the brain: 
1. Superficial cerebral veins 
2. Deep cerebral veins 
Both these veins drains into the dural venous sinuses, which further  
drains into the internal jugular vein . The cerebral veins lacks valves, they 
are thin walled, & the blood flow in these veins are in the same direction as 
that of the neighboring arteries.5 
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EPIDEMIOLOGY OF THE STROKE: 
          Apart from the ischemic heart disease & cancer, stroke remains one 
the most leading  causes of the death in the United States. Yearly around 
seven lakhs of stroke occurring – of  which 6/7 th are ischemic strokes and 
remaining 1/7 are hemorrhagic stroke. It remains the leading causes of the 
disability in adults. The calculated economic impact on the society is about 
$40 billion,6 both directly in health care & by the loss of income. By the 
various preventive measures the has been a steady decrease in the stroke 
occurrence to 54% over the last 30 years, in USA.  Incidence  of  stroke in 
the age group of  75-84 years in different countries include 1054 (France), 
2062 (Sweden). There was about 38% increase in the stroke in the women 
from the year 1975 to 1978 and 1983 to 1985.7 
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In India, community based stroke study was done in Vellore (1969-71), 
Rohtak (1971-74). The stroke contributes for around 4.6% of medical cases, 
20% of all the neurological cases admitted to the hospital.8 The Indian 
studies details are as below; 
1)  Incidence of stroke  -    119 to 145 per lakhs of population, 
2) Prevelance of stroke –     84 to 262 per lakhs of population (rural),  
                                           334 to 424 per lakhs of population (urban) 
3) Cases fatality rates – around 25% (urban population), 37% (rural 
population) are died due to stroke and its complication during 28 days 
of stroke. Mortality is highest in Kolkata studies (mortality rate – 
42%). 
4) IV thrombolysis of stroke –11% of the stroke.9 
5) Stroke subtypes – 68% cerebral infarct, 32% cerebral hemorrhage.10 
6) Stress hyperglycemia  prevelance – 14 – 60%.12 
7) Stroke contributes for 1.2%  of all death in the country.11 
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PREVALANCE RATE FOR STROKE IN RURAL INDIA (1970-2004) 
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PREVALANCE RATE FOR STROKE IN URBAN INDIA (1973-2004) 
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Stroke, the most common neurological diseases in adults, presents with 
clinical features of sudden onset (in a matter of second) of neurological 
deficit. Stroke can be divided into two main subtypes – ischemic or 
hemorrhagic stroke. Ischemic stroke arises as a result of occlusion of blood 
vessels to the brain which leads to sudden cut off of the blood supply leading 
cerebral infarction. 
Ischemic stroke is further divided into thrombotic stroke & embolic 
stroke. Based on underlying etiology, ischemic stroke, can arises from (1) 
atherosclerosis of large cerebral blood vessels, (2) occlusion of small 
cerebral vessel within brain parenchyma, (3) cerebral embolism. Several 
other causes of brain parenchyma infarction includes arterial dissection, 
vasculitis, hyper-coagulable state, cortical vein thrombosis. 
Transient ischemic attack (TIA), is defined as temporary neurological 
deficit caused by cerebrovascular disease, characterized by no clinical or 
imaging trace, with complete recovery occurring within 24 hours.13 Onset of 
stroke differs in ischemic and embolic stroke. The thrombotic stroke evolves 
over hours to days, in a saltatory fashion. In the embolic stroke, the onset is 
sudden, peak at once. The static onset & evolves over minutes is a feature in 
hemorrhagic stroke. 
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Stroke mimics:  
Various conditions like Migraine, Todd paralysis (seizure), Brain 
tumor, abscess will be imitating stroke and these condition should be 
considered in differential diagnosis. 
 
ISCHEMIC STROKE - RISK FACTORS: 
1. NON -MODIFIABLE: 
a) Age : the most important risk factor of the stoke, & the risk doubles 
after 55 years, for every decade. 
b) Sex : incidence and mortality of the stroke  is higher in male gender 
compared to that of female gender. 
c) Genetic factors : chromosome 12 polymorphism 
d) Race / Ethnicity : Afro Carrribeans> Asians > Europeans have 
stroke incidence in the decreasing order 
 
2. MODIFIABLE: 
a) Diabetes mellitus : 1.8 to 3.5 times increases in the stroke incidence, 
with most of them are lacunar strokes. Hyperglycemia and insulin resistance 
are the other risk factors.14 
b) Systemic hypertension : the most important risk factor in the 
development of ischemic stroke. The incidence is three times higher when 
compared to normotensive  people. Recent studies revealed that 46% 
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reduction in the stroke incidence for every 7.5 mmHg reduction in diastolic 
BP. Around 40% of strokes have a blood pressure of greater than 
140mmHg.15,16,17 
c) Dyslipidemia (elevated LDL cholesterol, elevated triglycerides) : 
Statin therapy reduce the stroke incidence by 20 -30%, because of its action 
of stabilizing the plaque, anti thrombotic action, improved endothelial 
function, and by reducing the inflammation.18 
d) Cigarette smoking : increases the risk of all types of stroke. The risk 
is highest in the younger group, with risk proportionate to the number of   
cigarettes smoked.19,20 
e) Alcohol intake : the risk is variable. Risk is reduced with low to 
moderate consumption. Higher level of consumption increases the incidence 
of hemorrhagic stroke. 
f) Obesity : along with smoking, a BMI of > 25 kg/m2, account for 
60% of stroke, in the group of men upto sixty five years. 
g) Transient ischemic attack (TIA) : 10 times higher risk of stroke 
when compared to person without stroke. 
 h) History of Stroke in the past 
i) Asymptomatic carotid bruit/stenosis 
j) Cardiac illness : the presence of left ventricular hypertrophy by ecg 
increases ischemic stroke risk by 10 fold,21,22presentation of congestive heart 
failure increases stroke incidence by nine fold. Atrial fibrillation raises the  
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risk of embolic stroke by 5 to 7 times than age matched population of normal 
cardiac rhythm. Other risk factors include mitral valve prolapsed, prosthetic 
valves, endocaritis, congenital heart diseases.23 
k) Aortic arch atheromatous diseases 
l) increased fibrinogen level 
m) Raised homocysteine level 
n) Decreased serum folate 
o) increased anti-cardiolipin antibodies 
p) Oral contraceptive use : risk is higher in young women who is 
taking estrogen content of more than 50 mcg. OCP increases ischemic stroke 
secondary to enhance platelet aggregation & alteration in clotting factors.24 
q) anticoagulation therapy: increases risk of hemorrhagic stroke. 
r) intake of low potassium, reduced serum potassium level 
 
  
22 
 
CLASSIFICATION OF STROKE  
Based on the pathogenesis: 
(A) Ischemic stroke – 
(i) With cerebral infarction: 
1. Cerebral thrombosis with or without atherosclerosis 
2. Cerebral embolism 
3. Cerebral venous thrombosis 
4. Vasculitis 
5. Cerebral anoxia 
6. Hematological disorder 
7. Complications due to angiography  
8. Aneursymal dissection affecting the brachiocephalic vessels 
9. Systemic hypotension, anoxic encephalopathy 
10. Unknown cause 
(ii) With cerebral ischemia: 
1. Transient ischemic attacks(TIA) 
2. Artery to artery embolism 
3. Paradoxical embolism 
4. Cardiac arrhythmias 
5. Arterial hypotension 
6. Migraine / Sub-arachnoid hemorrhage causing vasospasm 
23 
 
7. Idiopathic causes (drugs, consumptional coagulopathy, cerebral 
malaria, Behcet’s syndrome, cerebral amyloid angiopathy, 
hyperviscosity, hyperhomocysteinemia) 
 
     (b) Hemorrhagic stroke: 
                1. hypertensive cerebral hemorrhage 
                2. rupture aneurysm 
                3. trauma 
                4. blood dyscrasias 
                5. anticoagulation therapy or thrombolytic therapy 
                6. bleeding in the brain tumors 
                7. miscellaneous 
      (c) Stroke of undetermined origin: 
                1. leukariosis 
                2. Moyamoya disease 
                3. Fibromuscular dysplasia 
                4. Binswanger’s disease 
  5. Aortic arch syndrome 
  6. Winiwarterbuerger disease 
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(B) Clinical classification: 
        (1) Based on arterial territory: 
           (a) Anterior circulation stroke: 
                     - Anterior cerebral artery (ACA) syndrome 
                     - Middle cerebral artery (MCA) syndrome 
           (b) Posterior circulation stroke: 
                     - Vertebro basilar artery syndrome 
                     - Posterior cerebral artery syndrome 
        (2) Based on clinical manifestations: 
             (a) Transient ischemic attack – Focal neurological deficit with 
complete recovery within 24 hours 
             (b) Reversible ischemic neurological deficit – neurological deficit 
with complete recovery within one week. 
             (c) Evolving stroke : stuttering or gradual development of deficit 
             (d) complete stroke: rapid onset of stroke, with persistent 
neurological     
                  Deficit which does not progress beyond 96 hours.25 
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CAUSES OF STROKE IN DIFFERENT AGE GROUP 
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CAUSES OF CEREBRAL VASCULAR OCCLUSION AND 
ISCHEMIC STROKE: 
 
•   Cerebral vessel athero-thrombosis : 
Cerebral infarction occurs as results of – thrombus formed on plaque, 
artery to artery embolism, water shed infarct. Larger vessel involved in the 
site of branching point of the larger vessel. The sites involved are origin of 
the internal carotid artery from common carotid, the junction between 
vertebral & basiliar artery; middle cerebral artery involved mainly in the stem 
or its main bifurcation. Small vessel atherosclerosis mainly affects the 
lenticulo-striate branches (of middle cerebral artery), thalamo-striate branches 
(of posterior cerebral artery). This type of stroke evolves in stuttering fashion 
or intermittent progression over hours to days. Some of these stroke can also 
present in episodic fashion. Most of stroke this stroke occurred during sleep 
as a result of vascular stasis. 
• Cerebral embolism : Either from the cardiac source or from the artery 
to artery embolism. Cardioembolism accounts for around twenty percentage 
of  all ischemic strokes, arising  dueto embolism of thrombotic material 
forming on the endothelial surface of the heart. These strokes are sudden in 
onset, with maximum neurologic deficit atonce. The fragmentation of 
thrombus or quick lysis produces only transient ischemicattack (TIA). 
  
  
 
 
PATHOGENESIS OF DIRRERENT TYPES OF ISCHEMIC STROKE
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PATHOPHYSIOLOGY OF STROKE: 
CEREBRAL AUTOREGULATION   
Normally blood flow to the brain is mainly  depend up on the amount 
of  vascular resistance within cerebral blood vessels, which is related to their 
circumference.26Dilation of blood vessels leads to increased cerebral blood 
flow, whereas constriction of vessels has the opposite effect. Cerebral 
perfusion pressure also determine the cerebral blood flow. 
Cerebral autoregulation is the phenomenon by which maintaining the 
cerebral blood flow at a relatively constant rate despite variations in perfusion 
pressure. The mechanism by which auto-regulation occurs is not well 
understood, and may involve multiple pathways 
There are evidences which suggests that the smooth muscle in cerebral 
vessels can respond directly to changes in perfusion pressure, contracting 
when pressure increases and relaxing when pressure decreases. Reductions in 
cerebral blood flow may lead to cerebral vasodilatation due to release  
vasoactive substances, although the substance  responsible for this have not 
been identified. Nitric oxide which releasing from vascular endothelium 
appears to play a role in autoregulation. 
 
  
 
Cerebral blood flow is maintaining by autoregulation  which 
typically occurs within a range of 60 to 150 mmHg of mean arterial 
pressure. The upper and lower limits vary bet
however. Beyond  this range, the brain is unable to compensate for 
changes in perfusion pressure, and the cerebral blood flow increases or 
decreases passively with corresponding changes in pressure, resulting 
in the risk of ischemia at lo
 
29 
ween individuals, 
w pressures and edema at high pressures 
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Cerebral autoregulation during stroke   
 
Cerebral auto regulation is impaired due to some disease 
conditions,27,28 which includes ischemic stroke also .when cerebral 
perfusion pressure decrease there will be cerebral vascular dilatation  
and when it fall below the compensatory capacity of the brain it will 
lead to decrease in the cerebral blood flow  . Initially, the oxygen 
extraction fraction is increased in order to maintain levels of oxygen 
delivery to the brain. As the cerebral blood flow continues to fall, other 
mechanisms come into play.  
 
In patient with hypertension auto regulation is usually  occur at 
higher arterial pressures. Reduction of blood pressure to normal levels 
could actually exacerbate the derangement to autoregulation that 
occurs during stroke and lead to a further decrease in cerebral blood 
flow . 
  
 
 
 
CONSEQUENCES OF REDUCTION IN BLOOD FLOW 
DURING STROKE 
             The human brain is very much sensitive  to even a short 
durations of ischemia. Even though brain is only 2 to 3 percent of total 
body weight the blood flow it receives is about 20 percent of the total 
cardiac output. 
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The brain has no energy stores of its own, and therefore it 
depend on the blood for their delivery. So evena brief deprivation can 
lead to death of the affected brain tissue. During stroke, reduction of 
blood flow to brain results in a deprivation of glucose and oxygen . 
 
 
 
Commonly strokes are due to ischemia, which affecting the small part 
of the brain and mainly affecting a single blood vessel and its branches. 
Region which commonly involved is area supplied by the same vessel which 
is immediately surrounding the vessel. If the ischemia is prolonged in this 
area, cells will die by necrosis and the peripheral area which receives  
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nutrients and oxygen by collateral vessel will not die immediately, which can 
be revived by timely intervention and restoration of blood flow. This area 
which surrounds the dead cells is known as ischemic penumbra. And the area 
underwent necrosis is known as infarct.  
 
 
Mechanisms of ischemic cell injury and death : 
A sequence of events following the brain ischemia which leads to brain 
cell death. The possible mechanisms are  
1. ATP depletion 
2. Na+ ,K+ and Ca2+ ionic concentration changes 
3. Increase amount of lactic acid which leads to acidosis 
4. Oxygen free radicals 
5. Proteolytic enzymes  
6. Accumulation of water inside the cell 
 
 
 
 
  
  
As a consequence of the electrical failure that occurs as a result of 
ischemia, there will be increased secretion of 
the synapse will cause the glutamate receptor activation and lead to out flow 
of the potassium and inflow of the sodium and calcium ion .It will lead to 
variety of effects. The main subtypes of glutamate receptors involved a
1. N-methyl-
2. alpha-amino
 (AMPA) 
3. metabotropic glutamate receptors. Activation of these receptors 
 leads to membrane depolarization and increased calcium influx.
34 
excitatory neuro transmitter at 
D-aspartate (NMDA) receptor (main) 
-3-hydroxy-5-methyl-4-isoxazoleproprionic
 
re 
 acid  
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Another effect of NMDA receptor activation is the production of nitric 
oxide. Hypoxia leads onto the stimulation of the nitric oxide synthase, which 
results in the elevated levels of nitric oxide.    
 
Nitric oxide is plays a significant role in the signaling in the human 
body  at the  normal physiological range . As an example, endothelial nitric 
oxide synthase (eNOS) leads to the production of low levels of nitric oxide 
that cause vasodilation and increase blood flow.  However, neuronal nitric 
oxide synthase (nNOS) and inducible nitric oxide synthase (iNOS) result in 
larger amounts of nitric oxide that may lead to brain injury.  
 
Nitric oxide is a free radical and reacts directly with cellular 
components to damage them. Nitric oxide can also react with another free 
radical, superoxide, to produce the highly reactive peroxynitrite.  
Peroxynitrite causes single strand breaks in DNA. This results in the 
activation of DNA repair enzymes, which consume vital energy needed for 
other processes. DNA damage also may activate the process of apoptosis, 
leading to cell death. 
 
The production of reactive oxygen species, a normal byproduct of 
oxidative metabolism, is also increased during ischemia. Like nitric oxide, 
they can react with and damage cellular components. Injury to the plasma 
membrane of a cell can lead to the inability to control ion flux, resulting in 
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mitochondrial failure. Reactive oxygen species, as well as calcium influx and 
other factors, can also permeabilize the mitochondrial membrane. This leads 
to metabolic failure as well as the release of initiators of apoptosis and DNA 
damage.  
 
Metabolic failure results in the depletion of cellular ATP levels. ATP is 
required for nuclear condensation and DNA degradation in the final stages of 
apoptosis.  In the absence of ATP, cell death occurs by necrosis rather than 
apoptosis. The release of byproducts from cellular damage and death by 
necrosis activates components of the inflammatory pathway. The role that 
inflammation plays during ischemia is mixed, having both positive and 
negative effects. 
 
On way the surrounding inflammation results in proliferation of blood 
vessels and thereby increasing the blood flow to affected region.this will 
deliver more oxygen and glucose to the tissue . On the other hand, increased 
blood flow may also deliver more calcium to the area where the damage will 
be more. 
 
Inflammation also results in the migration of activated leukocytes to 
damaged tissue. Although these leukocytes may remove damaged and 
necrotic tissue, they also release cytokines to attract additional inflammatory 
cells. Under severe inflammatory conditions, these cytokines can accumulate 
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to toxic levels. The cell death can occur by two ways: either by the apoptosis, 
or by the necrosis. 
 
The pattern of cell death after cerebral ischemia depends on the nature 
of the insult to cerebral tissue. In global cerebral ischemia, such as occurs 
after cardiac arrest and resuscitation or transient severe systemic hypotension, 
the entire brain is exposed to ischemia. Formation of infarct is not immediate, 
but rather occurs after a delay of 12 hours to several days. Cell death is 
limited to those regions of the brain that are particularly susceptible to 
ischemic damage, such as the CA1 and CA4 regions of the hippocampus, the 
striatum, and cortical layers two and five. Cell death in these regions occurs 
primarily by apoptosis. 
 
Focal cerebral ischemia is a more common pattern than global 
ischemia in human stroke. In animal models of focal ischemia, changes in 
cell morphology are visible microscopically as early as two to three hours 
after the insult, and the infarct develops rapidly over a period of 6 to 24 
hours. Cell death occurs by necrosis in the core, with apoptotic cells located 
on the periphery. 
 
In addition to the type of insult, the duration of ischemia also affects 
the pattern by which cell death occurs. Longer ischemic insults produce 
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greater damage to cerebral tissue, resulting in an increased proportion of 
necrosis and decreased proportion of apoptosis. 
 
There have been few studies of apoptosis in the brain following stroke 
in human patients. However, accumulating evidence suggests that apoptosis 
is involved, as illustrated by the following observations29,30: 
 
• In a neuropathology study that compared specimens from 27 patients 
who had cerebral infarction with specimens from rat brains subjected 
to experimental transient forebrain ischemia, the patterns of cell death 
were similar in human and animal brain tissue and included both 
morphologic and histochemical findings typical of apoptosis .  In the 
human stroke specimens, apoptosis was apparent during the subacute 
stage, but was not seen in acute or chronic stages. 
 
• In another neuropathology report that compared 13 cases of fatal 
ischemic stroke with three patients who died of non-neurologic causes, 
histochemical and morphologic changes indicative of apoptosis were 
seen in cells throughout the brain of both patients and controls . The 
morphologic changes were more advanced in the peri-infarct region 
and infarct core of the patients with stroke. Apoptotic cells were 
located primarily within the peri-infarct region, consisting of up to 26 
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percent of all cells. Increased ischemic damage and neuronal necrosis 
was associated with a decrease in the percentage of apoptotic cells. 
 
The deciding factor in determining whether cells undergo 
necrosis or apoptosis seems to be the level of energy available in the 
form of ATP, which is required for formation of the apoptosome. 
Apoptosis is unable to proceed in its absence. 
 
When energy levels are limiting, cell death therefore occurs by 
necrosis rather than apoptosis. The role of ATP in the mechanism of 
cell death has been investigated primarily using cell culture models. 
Cultured neurons depend on the presence of serum in the culture 
medium for survival. If the serum is removed, the cells die by necrosis. 
In serum-free media with added glucose, however, the cells die by 
apoptosis. 
 
ATP levels are decreased in acute stroke because of decreased 
blood supply. Glucose metabolism is decreased by about 50 percent in 
both global and focal ischemia models of stroke. As a consequence, 
ATP levels may fall to 10 percent of normal in global models or 25 
percent in the infarct core in focal ischemia models. ATP levels in the 
penumbra, however, only drop to 50 percent to 70 percent of normal. 
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ATP levels in the brain may also be decreased  by mitochondrial 
damage or failure, activity of DNA repair enzymes, such as PARP, and 
neuronal depolarization related to glutamate excitotoxicity. In stroke, in the 
central area of infarction where the ATP level is least necrosis takes place 
whereas in the penumbra ATP levels will be slightly more than the central 
area and thereby apoptosis occurs. Hence the duration of ischemia directly 
related to the area of necrosis. 
 
Loss of brain structural integrity 
 
Occlusion of the blood supply to brain leads on to the disturbance in 
the integrity of blood vessels. This is mediated by the action of various 
substances like matrix metalloproteases (MMP), which destroy laminins, 
collagens in the blood vessels. The breach in the blood-brain-barrier will 
result in the formation of the cerebral edema resulting in raise in intra cranial 
hypertension. This will also results in the ischemic infarct developing 
complications like hemorrhagic transformation . 
 
Cerebral edema : 
Cerebral edema complicating stroke can cause secondary damage by 
several mechanisms, including increased intracranial pressure, which may 
decrease cerebral blood flow, and mass effect causing displacement of brain 
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tissue from one compartment to another (ie, herniation), a process that can be 
life-threatening. 
 
Two types of cerebral edema can occur as a consequence of ischemic 
stroke  
 
1. CYTOTOXIC EDEMA - The failure in the energy dependent 
pumping system (of Sodium &Calcium ) in the cell fails as a 
result of ischemia. This will leads on to the accumulation of 
water inside the cells, causing swelling of the neurons, and 
hence the brain. 
 
2. VASOGENIC EDEMA – The breakdown of the blood brain 
barrier will results in the leakage of osmatically active 
proteinous substance from the intravascular region  into the 
interstitial spaces of the brain, leading on to raised  extracellular 
fluid volume. 
 
About 10 percent of ischemic strokes may be massive because of 
the presence of space-occupying cerebral edema that may be  severe 
enough to produce elevated intracranial pressure and brain herniation.  
 
 
42 
 
CLINICAL FEATURES OF ISCHEMIC BASED 
ON ARTERIAL TERRITORY INVOLVEMENT 
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WATER SHED INFARCTS: 
            It occur in the border region between two arterial territory. These 
infarct are common during or after the surgery, severe arterial hypotension 
after cardiac arrest, prolonged hypoxemia, bilateral severe carotid artery 
diseases. 
 
           Ischemia in the border zone of the ACA, MCA & PCA manifest in the 
form of bilateral parieto-occipital infarcts with clinical features of visual 
disturbances, optic ataxia, cortical blindness and difficulty in predicting the 
size, distance and movement.  
 
            Unilateral severe arterial occlusion or stenosis will leads to unilateral 
watershed infarct when these is some degree of hemodynamic failure in these 
patients. This can also occur in the situation of microembolism or the 
hyperviscosity states. 
 
Ischemia between ACA & MCA region results in bilateral upper limb 
cortical sensorimotor impairment (man-in-barrel), impaired saccadic eye 
movements due to involvement of frontal eye fields. 
 
             MCA & PCA territory involvement results in bilateral parieto 
temporal infarction with cortical blindness, defect in the verbal & the non 
verbal material. dyslexia, dyscalculia, dysgraphia. 
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Watershed infarct can also occur in the regions of PICA, AICA & 
SCA., also involving internal watershed region in the centrum semi ovale 
near to & slightly above the body of lateral ventricles.  
 
MANAGEMENT OF ISCHEMIC STROKE: 
A) Initial evaluation: 
1. Management of airway, breathing, circulation 
2. Neurological examination to look for neurological deficit, and to 
localize into the arterial territory. 
3. Rule out possibility of stroke mimics – like hypoglycemia, 
hypertensive encephalopathy, seizures, etc. 
4. Secondary assessment of the neurological deficit and possible risk 
factors 
5. Etiology of the stroke to be assessed for early secondary prevention. 
 
B) History taking & examination: 
1. Time of onset of stroke – time when the patient was last seen to be 
symptom free. 
2. Circumstances around the development of the symptoms – whether 
at rest or during exertion. 
3. History suggestive of other potential causes of the symptom. 
4. History of medications – anticoagulants, anti-platelets agents 
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5. Evaluate for the risk factors like cardiac disease, arteriosclerosis, 
drug abuse, migraine, seizure, pregnancy. 
6. Assessment of airway, breathing, circulation – including pulse 
oximetry, blood glucose, body temperatue 
7. Looking for signs of trauma, carotid bruits, seizure activity ( 
contusions, tongue bite), congestive cardiac failure. 
8. Cardiovascular examination to search for valvular heart disesases, 
irregular rhythm, and associated heart diseases. 
9. Skin examination to detect coagulopathy, platetlet disorders, etc 
10. Grading of severity of stroke by using NIHSS scale, as this will 
important prognostic information. 
 
C) INVESTIGATIONS: 
1. Basic work-up including complete blood count, blood urea nitrogen, 
creatinine, electrolyte, liver function test, bleeding time, clotting time, 
prothrombin time, partial thromboplastin time, blood glucose level, 
lipid profile, chest X ray, electrocardiogram, urine analysis. 
2. Non contrast CT: 
This is the diagnostic brain imaging study in the initial stroke 
evaluation.31 
(A)  Hyperacute infarct (<12 hours): in this stage, there will be 
early changes in the form of grey-white matter differentiation will be 
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lost, sulcus & sylvian fissure effacement & obscuration  of the 
lentiform nucleus. Dense MCA sign- Horizontal part of the middle 
cerebral artery may appear hyperdense, even before the appearance of 
infarct. 
     (B) Subcute infarct (24-48 hours): 
Wedge shaped area of decreased  attenuation involving both the grey 
and with matter in a typical vascular territory. The initial mass effect then 
begins to decrease in 7-10 days. 
     (C) Chronic infarct: 
Well delineated, focal  areas of encephalmalacia appears in CT scans.  
Adjacent sulci become prominent and the ventricle on the ipsilateral side  
enlarges. Enhancement disappears after eight to ten weeks. 
Scan negative infarct: early scans may be negative in 60% of cases 32 
within12  hours of ictus, after 2 -3rd week after infarct (blooming). 
3. MULTIMODAL CT: 
i) Whole brain perfusion CT- identify the cerebral blood volume and 
areas of hypoattentuation  representing the ischemic core. 
ii) dynamic perfusion CT – provides absolute measures of cerebral 
blood flow, mean transit time and cerebral blood volume.  
iii) helical angiography – non invasive method to assess the 
vasculature of both the intra-cranially and extra- cranially and identify the 
stenosis or occlusion of the vessels.  
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4. Magnetic resonance imaging (MRI): 
o Superior in detecting ischemia, when compared with CT. 
o In acute infarct, DWI is highly sensitive in the first few hours 
after infarction. The diffusion restriction in acute infarct will 
appears as high intensity in DWI images with low ADC signal 
and appears dark, and during the initial stages T2 weighted 
images are normal. 
5. Multimodal MRI:  
o Diffusion weighted MRI (DWI) – identify ischemic regions 
within minutes of symptom onset and early identification of 
lesion size, site & age. 
The infarct volume on DWI  is calculated by using the product 
of “a”, “b”, “c” divided by 2, where the “a’ stands for the maximum 
length of the infarct, “b” stands for maximum breadth of the infarct, 
“c” stands height of infarct seen in the diffusion weighted images 
o Perfusion weighted MRI (PWI) – provides relative measures of 
cerebral hemodynamics. The ischemic penumbra is 
approximated on MRI as region of perfusion change without a 
corresponding diffusion abnormality (diffusion perfusion 
mismatch)33 
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6. MRI angiography: 
Delineates blood flow & vascular lesions, including 
atheromatous plaques in the carotid and vertebrabasiliar systems. 
Identify the larger blood vessel abnormality better than that of the 
distal lesions. 
 
7. Other brain imaging:–  includes oxygen-15 Positron emission 
tomography (PET); Xenon enhanced CT brain; Single photon 
emission computed tomography (SPECT) identifies thresholds of 
reversible ischemia; transcranial Doppler sonography for evaluation of 
the blood flow velocity and patency of the main intracranial arteries. 
 
8. Duplex Doppler ultrasonography - for detection of the carotid of the 
atheromatous plaques and obstruction of the carotid artery. 
 
9. Echocardiography to assess the potential causes of TIA or evolving 
stroke.34 
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TREATMENT: 
Treatment Of Acute Ischemic Stroke: 
 
(A) GENERAL SUPPORTIVE CARE 
a) Hypoxia worsens the outcome from the acute ischemic stroke. The 
airway protection and maintenance of the saturation is vital. Target oxygen 
saturation level is of 95%. 
 
b) Fever-Increased metabolism, increased release of neurotransmitters, 
and increased free radical production is the possible mechanism responsible 
for worsening of the stroke by the fever.Antipyretic medications and cooling 
devices are advised measures to reduce fever.35 
Hypothermia has been shown to be neuroprotective after experimental 
global and focal hypoxic brain injury.  
 
c) Arterial hypertension:  
The increase in BP can be due the stress caused by ischemic event, 
distended bladder, prior hypertension, as result of hypoxia, or raised  
intracranial pressure. Aggressive control of BP in all cases can be 
detrimental, as the raise in blood pressure can be a result of protective auto 
regulatory mechanism. 
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Indications for reduction in blood pressure in ischemic stroke – when 
systolic BP > 220 mmHg, diastolic BP > 120 mmHg.36Or else when the raise 
in BP is associated with symptoms of heart failure, aortic dissection, acute 
coronary syndrome, hypertensive encephalopathy, renal failure. When patient 
is taken for IV thrombolytic therapy, the target BP is of < 185/110 mmHg 
prior to thrombolysis, and < 180/105 mmHg post thrombolysis. 
 
d) Arterial Hypotension: 
Correcting the state of hypovolemia with isotonic fluids, correcting the 
patient abnormal rhythm- to slow down the ventricular response in patient 
with AF with higher ventricular rate. If these effort fails, vasopressor should 
be considered. 
 
e) Hypoglycemia:   
Hypoglycemia can cause focal neurological signs, and hence the 
correction of the hypoglycemia is vital. 
 
f)  Diabetes mellitus - Hyperglycemia is associated with poor outcomes.37 
 
B] REPERFUSION MEASURES: 
(i) Thrombolytic therapy 
The NINDS study used IV rtPA (0.9 mg/kg to a 90-mg max; 10% as a 
bolus,then the remainder over 60 min) within 3 h of onset resulted in good 
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functionaloutcome though incidence of hemorrhage increased after 
thrombolysis Those withNIHSS score < 20responds well to the treatment. 
 
In ECASS-II, IV rtPAwas not that much effective (in comparing with 
the placebo) in the final outcome of the stroke. 
 
In the multicenter acute stroke trial Europe study group (MAST-E), 
streptokinase in the dose of 1.5 million units over one hour was associated 
with hemorrhagic transformation of ischemic infarct and hence not 
recommended. Intra-arterial thrombolysis has its role in cases of large artery 
occlusion, when intervention is done within six hours from  the onset of the 
stroke .  It is not FDA approved. 
 
(ii) Anticoagulants 
According to the Joint Guideline Statement from the AHA and AAN, 
urgent routine anticoagulation with the goal of improving neurological 
outcomes or preventing early recurrent stroke is not recommended as it is 
associated with increased risk of bleeding complications38 
 
(iii) Antiplatelet Agents 
a) Aspirin 
The International Stroke Trial (IST) showed a greater  reduction in  
recurrence of  the  ischemic events by aspirin within the two  weeks, but no 
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role in reducing the acute mortality . At 6 months, patients assigned aspirin 
had a significantly lower incidence of death and dependency.39 
The Chinese Acute Stroke Trial (CAST) showed that  aspirin reduced 
the mortality due to the stroke, but the role in reducing the long term 
mortality and morbidity is not improved.40 
A combined result suggested that aspirin was beneficial in reducing 
recurrence of the  ischemic stroke, death, or dependency. 
 
b) Ticlopidine 
In the ticlopidine aspirin stroke study, the risk of non fatal stroke or 
death from any cause at 3 years was lower in ticlopidine group as compared 
to aspirin group. The 3 year risk of fatal or non fatal risk was also lower 
.Thus it was concluded that ticlopidine was more effective than aspirin. The 
Canadian American ticlopidine study concluded that an exclusive benefit 
cannot be claimed for ticlopidine over aspirin in treating patients with stroke. 
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c) Clopidogrel 
It is a theinopyridine derivative which is a potent inhibitor of platelet 
aggregation caused by ADP. In a trial recent stroke/TIA patients were 
randomized to receive clopidogrel 75 mg/ day as compared with clopidogrel 
75 mg/day with low dose aspirin 75 mg/day, showed no statistically 
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significant difference in outcome between the two treatment groups. 
Clopidogrel can be given to patients allergic to aspirin.42 
 
(C) NEUROPROTECTIVE AGENTS 
Hypothermia is probably the most powerful neuroprotectant.  Various 
drugs have been tried like calcium channel antagonists (nicardipin, 
nimodipine), NMDA receptor agonist (selfolate, eliprodil), ICAM – I 
antibodies (Enlimomab), GABAnergic antagonists (Diazepam, 
Clomethiozole), glutamate antagonists (leleluzole),  free radical scavengers 
(tirilazed, dihydrolipoate), lipid peroxidation inhibitors (Ebselen). Many of 
these drugs are in experimental stages and further studies are required before 
routine use . 
 
(D) SURGICAL INTERVENTIONS 
The MERCI (Mechanical Embolus Removal in Cerebral Ischemia) 
single-arm trial investigated endovascular thrombectomy to restore patency 
of occluded intracranial vessels within 8 h of ischemic stroke symptoms. 
Recanalization of the target vessel occurred in 48% of treated patients and in 
60% following use of adjuvant endovascular methods, and successful 
recanalization at 90 days correlated well with favorable outcome. The North 
American Symptomatic Carotid Endarterectomy Trial (NASCET) and the 
European Carotid Surgery Trial (ECST) evaluated patients with symptomatic 
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stenosis of carotid arteries found a substantial benefits in patients with a 
stenosis of > 70%. 43 
 
(E) MANAGEMENT OF THE COMPLICATIONS: 
(a) Raise in Increased Intracranial Pressure : 
The goals of management of brain edema are to 
• Reduce ICP  
• Preserve perfusion to the brain 
• Avoiding the herniation of the brain 
 
Osmotic therapy (Mannitol)  and hyperventilation have a vital role in 
reducing the ICP. The usage of the steroid in reducing the ICP secondary to 
stroke is not advisable. Decompressive surgery & evacuating the cerebellar 
infarcted areas causing the brain stem compression which leading to cause  
hydrocephalus are  advisable.44 
 
(b) Seizures 
Usually on the first day of the stroke pateints are prone for developing 
seizures, which can be either focal or generalized seizures. The recurrent 
episodes are common in around twenty to eighty percentage of the cases. The 
role of prophylactic anti- epileptic therapy is not indicated 
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(c) Hemorrhagic Transformation 
The use of all antithrombotic, but especially anticoagulants and 
thrombolytic agents, increases the likelihood of serious hemorrhagic 
transformation. The early use of aspirin also is associated with a small 
increase in the risk of clinically detectable hemorrhage.Management of 
patients with hemorrhagic infarction depends on the amount of bleeding and 
its symptoms. 
 
RECOVERY FROM THE STROKE: 
Usually most stoke recovery occurs in two to three months. 90% of 
recovery almost occurred within 2-3 years. Diabetes mellitus, prior stroke, 
cardiac diseases, ECG abnormality, prior functional dependence, severe 
motor deficits, sensory and visual deficit, loss of consciousness, cognitive 
deficit, incontinence are associated with poor outcome. 
       Recovery is better in the legs compared to the arm. The lack of 
measurable grip strength by 4 weeks following the stroke is a less favourable 
sign. Language function recovery is variable. The recovery is best for anomic 
aphasia, worst in the cases of global aphasia. Recovery from aphasia appears 
to occur independently of recovery from the hemiparesis. The recovery is 
better with usage of certain drugs like cholinergic, anticholinesterase, 
amphetamines, L-dopa, phenylephrine. 
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VITAMIN D: 
McCollum, in the year 1922, discovered a new vitamin, which was the 
fourth vitamin identified at that time, and he named it as Vitamin D, 
representing the fourth letter of the alphabetical. It is the only vitamin in the 
body which can be synthesized in the human body itself. To be strict, vitamin 
D should be consider as a pro-hormone rather than a vitamin, as this can be 
synthesized in the body.  
Vitamin D is essential in maintaining the normal calcium, phosphate 
levels in the blood. It is also required endocrine effect on calcium, thereby 
maintaining the normal mineralization of the bone. Other essential functions 
of Vitamin D include muscle contraction, nerve conduction, immune 
function, role in the inflammation in the form of cell proliferation and 
differentiation. Vitamin D insufficiency increase the risk for developing 
insulin resistance, Type-1 DM, hypertension, depression. 
Calcitriol is the active form of the vitamin D. This active form of the 
vitamin is required for transcription of number of vitamin D dependent genes 
coding for protein regulating with calcium transport, bone matrix protein. 
Vitamin D synthesis start in the skin, wherein the sunlight exposure (UV B), 
converts the 7-dehydrocholestrol to vitamin D3 (also called as 
cholecalciferol). Thedietary source of vitamin D is mainly from the fish oil, 
egg yolk (vitamin D3), plant source. The plant source contains vitamin D2 
(ergocalciferol). 
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SYNTHESIS OF VITAMIN - D 
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In circulation, Vitamin D is bounds to plasma protein mainly  
α-globulin, albumin. These two forms of inactive vitamin requires two step 
activation which takes place in the liver followed by kidney.The inactive 
forms are taken up by the liver, where, it undergoes 25-(OH) hydroxylation 
by the enzyme 25-hydroxylase, which is not tightly regulated,  resulting in 
formation of 25-(OH) vitamin D3 and this forms the major storage 
component of vitamin-D.  
 
Further activation takes place in the proximal convoluted tubules of the 
kidney, keratinocytes  by the action of 1-hydroxylase, resulting in synthesis 
of 1,25–(OH)2 Vitamin D3. 1-hydroxylase is the rate limiting enzyme in the 
synthesis of active form of vit-D3, which is stimulated by parathormone, 
hypophosphatemia and is inhibited FGF 23, calcium.  
 
 
The active vitamin undergoes entero-hepatic circulation, where it is 
dehydroxylated and the vitamin is converted into inactive form. The active 
form of vitamin D acts on the vitamin D receptor in the nucleus, resulting in 
transcription of genes necessary for calcium absorption and bone resorption. 
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Risk factors for Vitamin D deficiency includes old age, decreased 
sunlight exposure, dark skinned individual, obesity, fat malabsorption. 
Vitamin D deficiency can results due to  decreased synthesis in the skin, 
decreased intake of Vitamin D, increased loss of vitamin  D as a result of 
small bowel diseases, drug like barbiturates, phenytoin, rifampicin causing 
enzyme induction;  isoniazid causing impaired 25-hydroxylation leading to 
rare causes of Vitamin D deficiency.   
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The vitamin D deficiency prevalence in India is high, and according to 
studies upto 90% of indian are found to have hypovitaminosis, of which 
around forty to forty five percent of population have vitamin D deficiency. 
The ethnic differences in the vitamin levels been reported early with higher 
level of vitamin D deficiency in Indian population than that of the age and 
sex matched Chinese population. 
 
The clinical features include skeletal manifestations including rickets, 
osteomalacia, proximal muscle weakness,muscle soreness, bone pain, 
numbness, tingling sensation due to hypocalcemia. Decreased levels of 25-
hydroxyvitamin D was found to be associated with cardiovascular diseases in 
form of atherosclerosis, coronary calcification.  
 
Multiple recent studies found that decreased level of 25-
hydroxyvitamin D is associated with carotid plaques and higher intimal 
media thickness valve, larger artery atherosclerosis, and smaller vessel 
diseases. Various studies revealed that vitamin D deficiency is identified as 
independent risk factor for the development of arterial hypertension, ischemic 
stroke (both thrombotic & embolic stroke). But the interventional studies 
involving vitamin D supplementation has no evidence to show that 
supplementation reduces the stroke incidence. 
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VITAMIN-D AND STROKE: 
 
           Vitamin D deficiency is identified as independent risk factor for 
development of stroke49. It is associated with severity of stroke, higher infarct 
volume, poor early functional recovery following stroke. Vitamin D 
deficiency increases stroke risk indirectly by causing hypertension, obesity. 
The decreased level of Vitamin D causes: 
 
ACTIONS OF VITAMIN - D 
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(1) Increased Paratharmone levels – acute raise in PTH causes 
vasodilation, chronically increased PTH levels causes 
vasocontriction,; this high PTH levels are feature of Vitamin D 
deficiency,  which leads to development of hypertension. 
 
(2)  Vitamin D has anti atherosclerotic, anti-inflammatory action. 
Decreased levels favour atherosclerosis. 
 
(3) Anti-hypertensive effect of Vitamin D is by suppression of renin- 
angiotension-aldosterone, whish is lost in deficient state. 
 
(4) Also, the renal protective effects & anti proteinuric effect is blunted 
in deficient state. 
 
(5) Dysregulated inflammatory response, decreased Insulin like growth 
factor (IGF-1) leads to reduced neuro-protective actions48 
 
(6) Reduced cognitive functions 
 
Vitamin D deficiency diagnosis and management: 
 
-The Vitamin D deficiency is assessed by measuring the level of 25- 
dihydroxyViatmin D in the serum. The is no specific concensus on the 
method of vitamin D assessment, and the level of deficient state. Vitamin D 
is assessed by chemiluminescent microparticle immunoassay (CMIA).47 
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(1) > 30ng/ml        - considered normal50 
(2) 10-30ng/ml       - mild deficiency 
(3) < 10ng/ml         - severe deficiency 
 
- Recommended daily amount for Vitamin D: is depends on the age. 
For people less than seventy year – 15 microgram per day or 600 
IU/day. For people seventy year or above – 20 microgram per day or 
800 IU/day . 
 
- Vitamin D deficiency is treated with 50,000IU/week  for around six to 
eight weeks, then followed by maintenance dose of 800IU/day. 
 
- VitaminD toxicity occurs when daily consumption is more than 
4000IU/day. 
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HYPERGLYCEMIA AND STROKE 
 
Hyperglycemia is a commonly associated metabolic abnormality in 
patient with stroke. The presence of hyperglycemia in stroke on admission is 
associated with poor prognosis. Stroke associated with hyperglycemia is 
characterized by larger infarct volume with greater increases in infarct 
volume on subsequent days, with higher level of disability (neurological 
deficit), with higher mortality and morbidity. 
 
Stress hyperglycemia or in hospital hyperglycemia is present any blood 
glucose valve >140 mg/dl.51 The frequency of stroke associated with 
hyperglycemia ranges from around 2/3 in all ischemic strokes, and around 
almost half of the patients with lacunar stroke. 
 
 The incidence of hyperglycemia during admission for stroke in a prior 
non-diabetic individual is 8-62% and in a known diabetic individual is 39% 
to 83%. This stress hyperglycemia is a state of pre-existing abnormal glucose 
metabolism, precipitated by stressful event in the form of stroke.  
 
During follow up, about 27% to 37% of the patients were found to be 
have impaired glucose tolerance, with 1/3 of the remaining persons 
subsequently developed  diabetes mellitus during next one year. On 
continuous monitoring of the glycemic status during the stay in the hospital 
will reveals that this early phase of hyperglycemia last for around 24 hours of 
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development of stroke, then reaches near the normoglycemic status, will later 
goes through a period of late hyperglycemia. The mortality is increased 18 
fold in non-diabetic patients admitting with stroke and having hyperglycemia, 
wherein 3 fold increase in mortality rate in  diabetic patient having 
hyperglycemia  on admission. 
 
 According to recent studies, the ischemic stroke involving cortex & 
having stress hyperglycemia is associated with poor outcomes, where in cases 
of lacunar infarct this is correlation is not true, and this is associated with 
better outcome. 
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The infarct volume changes with as days progress with maximum 
volume is reached around 3-5th day after stroke52, following which infarct 
volume decreases and attains stable volume around 90th day. The 
hyperglycemia is associated with higher infarct volume on admission, along 
with larger raise in the volume on subsequent days.  
 
Stroke associated stress hyperglycemia are more prone for 
hemorrhagic transformation of the acute infarct, and also associated with 
poor outcomes with intravenous thrombolytics therapy; these patients 
develops hemorrhagic complications with thrombolytic therapy more 
frequently than that stroke patient with normoglycemic status. 
 
Pathogenesis of  stress hyperglycemia and stroke progression: 
# stroke causes a generalized stress reaction, which leads to stimulation 
of HPA axis. This leads to increased secretion of hormones like glucagon, 
corticosteroids, epinephrine, growth hormone resulting in hyperglycemia. 
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EFFECT OF HYPERGLYCEMIA  
 
 
 
• The HPA axis stimulation is probably from the supra-pituitary level, 
mainly more when the insular cortex is affected in the stroke.  
• Increased levels of stress hormone leads to glucogenolysis, decreased 
glucose uptake, with  increased lipolysis, increased protein breakdown. 
These effect leads to hyperglycemia, which causes circulatory and 
tissue effects in the form of volume depletion, hypoperfusion, and 
electrolyte imbalance, with endothelial dysfunction leading to 
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vasoconstriction and platelet dysfunction, mitochondrial    dysfunction. 
All these results in systemic hypoperfusion, infection, sepsis, multi   
organ failure and finally death. 
• Hyperglycemia causes osmatic diuresis,  volume depletion, 
hypotension, anaerobic metabolism leading to lactic acidosis. 
Excessive reactive oxygen  species causes lipid peroxidation of the cell 
wall leading to cell wall lysis. 
• Epinephrine excessive state causes decreased intake of glucose into the 
cell Leading to hyperglycemia and excessive insulin secreation and 
insulin resistance. 
• Hyperglycemia causes damage to the blood brain barrier by reactive 
oxygen species formation and lipid peroxidation. 
• Hyperglycemia triggers the glutamate mediated spreading of the 
depression waves of injury 
 
HYPERGLYCEMIA AND AGGRAVATED CEREBRAL DAMAGE: 
A) Impaired recanalization53: 
• Increased thrombin/ Anti- thrombin complex 
• Tissue factor pathway activation 
• Decreased recombinant tissue plasminogen activator activity 
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B) Decreased reperfusion:   hyperglycemia leading onto:- 
• Decreased Nitric oxide 
• Increased prostaglandins 
 
C) Direct tissue injury: 
• Anaerobic glycolysis 
• Mitochondrial dysfunction 
 
D) Increased reperfusion injury: 
• Oxidative stress 
• Inflammatory response 
• Cytokines causing tissue damage 
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NATIONAL INSTITUTE OF HEALTH STROKE SCALE (NIHSS) 
 
The Quantitative assessment of the stroke – related neurologic  
Deficit is assessed by using National Institute Of Health Stroke Scale 
(NIHSS). In this scale the  neurological deficit is assessed byevaluating the 
motor functions, visual fields, ataxia, speech, language, cognition and sensory 
impairments.  Score were given to calculate the deficit in each function 
individually and  then combined totally  for a total score. The higher the 
neurological functional loss, greater will be the NIHSS score. This scale 
provides a clinical tool for documentation of  the neurological deficit.  The 
scale also give information about the severity of the lesion, correlates well 
with the severity of the stroke, mortality and functional outcome. It serves for 
planning patient care and provides a common language for information 
exchange among health care providers. The NIHSS is a 15- item neurologic 
examination stroke scale used to evaluate the effect of acute cerebral 
infarction on the levels of consciousness, language,  neglect, visual – field 
loss, extraocular movement, motor strength, ataxia, dysarthria and sensory 
loss. Scores less than five indicate mild neurological impairment, between 
five to fifteen means  mild to moderately severe impairment, between fifteen 
to twenty five  indicates severe impairment and scores greater than means 
very severe impairment.  One additional point on the baseline decreased by 
24% the likelihood of survival and excellent outcome at 7 days and by 17% at 
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3 months.The outcome is favourable when the bseline  NIHSS score is low, 
with smaller vessel involvement. 
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MATERIALS AND METHODS 
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MATERIALS AND METHODS 
SETTING:  
This study was conducted at the Institute of Internal Medicine,  
Rajiv Gandhi Government General Hospital, Madras Medical College, 
Chennai. 
 
ETHICAL COMMITTEE APPROVAL: 
Obtained. 
 
STUDY DESIGN: 
This study was conducted over a period of six months. 
 
STUDY POPULTION: 
Patients admitted with Acute ischemic stroke to the  medical wards, 
Institute of Internal Medicine. 
 
SAMPLE SIZE: 
Fifty patients 
 
TYPE OF STUDY:  
Observational study 
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INCLUSION CRITERIA: 
• Ischemic stroke patients admitting within 24 hours  
 
EXCLUSION CRITERIA: 
• History of previous ischemic stroke in the past. 
• Any evidence of hemorrhage on CT BRAIN 
• Massive infarct on imaging 
• Patients selected for thrombolytic therapy. 
• Transient ischemic attacks 
• Cortical venous thrombosis 
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DATA COLLECTIONS AND METHODS 
 
Informed consent obtained from each patients.  Patients have their 
history taken according to the Questionnaire and subjected to clinical 
examination, NIHSS scale assessment. 
 
On the time of the admission, the glycemic status of the patient is 
assessed by measuring the capillary blood glucose (CBG) levels, irrespective 
of the last meal status. Subsequently, during the stay in the hospital, blood 
glucose levels are monitored by using fasting and post prandial blood sugar 
levels. 
 
 During the admission, patients with ischemic stroke without evidence 
of hemorrhage in the CT Brain, was subjected to MRI Brain/MRA/MRV 
within 24 hours of onset of the neurological deficit. Then a repeat MRI 
Brain/MRA/MRV done on the 3-7th day. Then the volume of the ischemic 
stroke is assessed by using the Diffusion weighted images (DWI). The 
volume is calculated by using the product of “a”, “b”, “c” divided by 2, 
where the “a’ stands for the maximum length of the infarct, “b” stands for 
maximum breadth of the infarct, “c” stands height of infarct seen in the 
diffusion weighted images. 
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The volume of the infarct on the day one, volume of infarct on the day 
3-7 is calculated, and the rise in the volume of infarct is measured by the 
difference between these two volume. These three volume are correlated with 
the capillary blood glucose (CBG) obtained during the admission. 
 
The levels of Vitamin D [25-OH Vit D3 (total)] assessed by using 
chemi-luminescent immunoassay (CMIA), during the period of stay in the 
hospital.  Then the patient classified  based on vitamin D levels into normal 
(30-100 ng/ml) , insufficiency (10-30 ng/ml), deficiency (< 10 ng/ml). 
  
All the data will be entered in the proforma (enclosed).  
The data will be analysed by using SPSS package and ANOVA.  
 
 
 
 
 
 
 
 
  
 
 
 
OBSERVATION AND RESULTS 
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OBSERVATION & RESULTS 
 
AGE DISTRIBUTION:               
 
AGE (Years) NUMBER OF PATIENTS “p” valve 
<= 30 3 
 
0.733 
(not significant) 
 
31-40 8 
41-50 9 
51-60 11 
61-70 8 
71-80 8 
> 80 3 
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SEX DISTRIBUTION:  
 
SEX NUMBER OF PATIENTS PERCENTAGE “p” valve 
Male 29 58 
0.726 
(not significant) 
Female 21 42 
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VITAMIN D LEVELS: 
 
VITAMIN D LEVEL 
NUMBER OF 
PATIENTS 
P -VALVE 
Normal 37 
<0.001** 
(HIGHLY 
SIGNIFICANT) 
Insufficiency 8 
Deficiency 5 
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VITAMIN - D LEVELS IN DIFFERENT AGE GROUP: 
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GLYCEMIC STATUS ON ADMISSION: 
 
 
 
 
  
 
CBG < 140 mg/dl CBG  ≥140 mg/dl 
MALE 18 11 
FEMALE 12 9 
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GLYCEMIC STATUS ON ADMISSION: 
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INFARCT VOLUME ON DAY 1 COMPARISON WITH CBG ON 
ADMISSION: 
 
 
 
CBG ON 
ADMISSION 
(mg/dl) 
NUMBER 
OF 
PATIENTS 
MEAN 
VOLUME 
(cm3) 
STANDARD  
DEVIATION 
P VALVE 
INFARCT 
VOLUME IN < 
24 HOURS 
< 140 30 14.03 4.723 <0.001** 
(Highly 
Significant ) 
 
≥ 140 20 21.15 6.02 
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INFARCT VOLUME ON DAY 1 COMPARISON WITH CBG  
ON ADMISSION 
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INFARCT VOLUME ON DAY 3-7 COMPARISON WITH CBG  
ON ADMISSION: 
 
 
 
 
 
 
 
 
 
 
CBG on 
Admission 
(in mg/dl) 
Number 
of 
patients 
Mean 
volume 
(cm3) 
Standard 
Deviation 
P -valve 
Infarct Volume on  
3-7 Days 
 
< 140 30 26.1 8.206 
<0.001** 
(Highly 
Significant ) 
≥ 140 20 42.15 9.138 
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INFARCT VOLUME ON DAY 3-7 COMPARISON WITH CBG  
ON ADMISSION: 
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CHANGE IN INFARCT VOLUME  COMPARISON WITH CBG ON 
ADMISSION: 
 
 
 
 
 
 
 
 
 CBG ON 
ADMISSION 
(IN MG/DL) 
NUMBER 
OF 
PATIENTS 
MEAN 
VOLUME 
(CM3) 
STANDARD 
DEVIATION 
P -VALVE 
CHANGE IN 
INFARCT 
VOLUME 
< 140 30 12.1 4.559 
<0.001** 
(Highly 
Significant ) 
≥ 140 20 21.4 4.672 
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CHANGE IN INFARCT VOLUME  COMPARISON WITH  
CBG ON ADMISSION 
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COMPARISON OF CBG ON ADMISSION WITH NIHSS: 
 
 
 
 
 
 
 
 
 
 
CBG ON 
ADMISSION 
(MG/DL) 
NUMBER 
OF 
PATIENTS 
MEAN 
VOLUME 
(CM3) 
STANDARD 
DEVIATION 
P -VALVE 
NIHSS ON  
ADMISSION 
< 140 30 11.03 3.243 <0.001** 
(Highly 
Significant ) 
 
≥ 140 20 18.95 4.123 
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COMPARISON OF CBG ON ADMISSION WITH NIHSS 
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RESULTS 
 
AGE DISRIBUTION: 
 
In our study among the ischemic stroke patients, the mean age of 
incidence is 55.86 years. In this, 6% were in the age group of less than 30 
years, 16% were in the age group of 31 to 40 years, 18% were in the age 
group of 41 to 50 years,  22% were in the age group of 51 to 60 years, 16% 
were in the age group of 61 to 70 years, 16% were in the age group of 71 to 
80 years, 6% were in the age group of  > 80 years. 
 
SEX DISTRIBUTION: 
 
In our study among the ischemic stroke group, 58% were males, 42% 
were females. 
 
 
VITAMIN D LEVELS IN THE ISCHEMIC STROKE PATIENTS: 
 
In our study, 74% of the patients had normal levels of Vitamin D, 16% 
of the patients had Vitamin D insufficiency, and 10% of the patients had 
Vitamin D deficiency. Of the Vitamin D deficient individuals, 3 were males, 
and 2 were females. The correlation between ischemic stroke and Vitamin D 
deficiency is highly significant (< 0.001**). 
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GLYCEMIC STATUS ON ADMISSION: 
In the study group, 60% were euglycemic on admission, and 40% were 
hyperglycemia on admission. Of the hyperglycemic patients, 11 patients were 
males and 9 patients were females. 
 
CORRELATION BETWEEN GLYCEMIC STATUS ON ADMISSION  
AND INFARCT VOLUME: 
 
In the study group, patient with euglycemic status on admission had a 
mean infarct volume of 14.03 cm3 (in < 24 hours), 26.10 cm3 (between 3th to 
7th day after ischemic stroke), with a mean increase in the infarct volume of  
12.10 cm3. 
 
In the patient with hyperglycemic status on admission had a mean 
infarct volume of 21.15 cm3 (in < 24 hours), 42.15 cm3 (between 3 to 7th day 
after ischemic stroke), with a mean increase in the infarct volume of 21.40 
cm3. 
 
The infarct volume in < 24 hours, between 3rd to 7th days of the 
ischemic stroke  and there progression is higher in hyperglycemic patients 
compared to that of the euglycemic patients, and these changes are highly 
significant (<0.001**) 
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CORRELATION BETWEEN GLYCEMIC STATUS AND NATIONAL 
INSTITUTE OF HEALTH STROKE SCALE (NIHSS): 
 
In the study group, the mean NIHSS score in euglycemic group is  
11.03 cm3, where is in the hyperglycemic group the mean NIHSS score is  
18.95 cm3. 
 
  
  
 
 
 
DISCUSSION 
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DISCUSSION 
 
• In a study by Bravata D. M. et al  the mean age of the ischemic stroke 
is 73 ± 13 years. The mean age of male patients was  61.16 ± 14.88 
years and the mean age of female patients was 57.33 ± 12.07yearsin 
Hyvarinen M et al study.  In our study the mean age of occurrence is  
55.86 years. The youngest patient was aged 15 years and the oldest 
was 85years. Maximum number of patients were in the age group of 51 
– 60 years. 
 
• Kushner et al in their study reported M : F ratio was 1.7 : 1.5. 
Hyvarinen M et alreported 55% men and 45% women in their study of 
21,706 cases. In our study the incidence in male is 58% and in female 
42%. The male: female ratio is 1.38: 1. 
 
• In Jaydip Ray Chaudhuri et al studies, vitamin D deficiency had an 
independent association with the ischemic stroke. In our study also, 
the Vitamin D deficiency occurred in 10% of the cases, and 
insufficiency in 16% of the cases. 
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• In study done by Sarkar RN et al 38% had diabetics in their study of 
450 patients.  In this study, stress hyperglycemia was defined as 
admission blood glucose levels > 140 mg / dl. In our study the 
hyperglycemia cut-off is set as ≥ 140 mg/dl. 
 
• Jhanghorbani M et al noted a stronger association between 
hyperglycemia and stroke in women than in men.   In this study, 40% 
had hyperglycemia on admission, while remaining 60% are   
Euglycemic on admission. Of this, 37.93% of male are hyperglycemic, 
and 42.85% of female had hyperglycemia on admission. In this study, 
the random blood glucose on admission ranged from 90 mg/dl to 455 
mg/dl. The range of blood glucose was 90 – 140 mg/ dl in the 
normoglycemic group. Most of the hyperglycemic patients had 
admission blood glucose between 140 – 220 mg/dl. Two patients  had 
blood glucose > 400 mg/ dl on admission. 
 
• Gentile NT et al noted that hyperglycemia was associated with higher 
admission NIHSS severity score. In our study, the mean NIHSS score 
is 18.95 in hyperglycemic patients and 11.03 in euglycemic patients. 
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• In studies by Tracey A Baird et al, hyperglycemia is associated with 
higher infarct on admission, and there progression is higher compared 
to that of the normoglycemic group. In our study group, patient with 
euglycemic status on admission had a mean infarct volume of 14.03 
cm3 (in < 24 hours), 26.10 cm3 (between 3th to 7th day after ischemic 
stroke), with a mean increase in the infarct volume of 12.10 cm3. In 
the patient with hyperglycemic status on admission had a mean infarct 
volume of 21.15 cm3 (in < 24 hours), 42.15 cm3 (between 3 to 7th day 
after ischemic stroke), with a mean increase in the infarct volume of 
21.40 cm3. 
 
• This shows that admission hyperglycemia is associated with higher 
infarct volume & greater progression of the infarct when compared 
with that of the euglycemia on admission.  
 
 
 
 
 
 
 
 
  
 
 
 
CONCLUSION 
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CONCLUSION 
 
• According to our study, the hyperglycemia on admission is associated 
with greater infarct volume on admission, greater raise in the infarct 
volume in the subsequent days, with higher change in volume of 
infarct in the patient with hyperglycemia on admission, when 
compared that of the normoglycemia on admission. 
 
• The vitamin D deficiency appears to be an independent correlation 
with the ischemic stroke. 
 
 
 
 
 
 
 
 
 
  
 
 
 
LIMITATIONS 
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LIMITATION OF THE STUDY 
 
• One limitation of this study is that the number of patients included in 
the study is less and so this study should be tested in studies involving 
larger number of patients. 
 
• The management of the hyperglycemia and stroke per sec were not 
standardized. 
 
• Extended follow up of the patients was not possible. 
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ANNEXURES 
  
  “A STUDY ON VITAMIN-D LEVEL AND GLYCEMIC STATUS IN       
                 ACUTE ISCHEMIC STROKE AND THEIR IMPACT” 
PROFORMA: 
Name :                                                   Patient ID No: 
Age/Sex :    Contact Address & Phone No: 
Occupation  : 
 
Symptoms: 
 
Past history: 
*Diabetes mellitus: 
*Hypertension 
*Heart diseases 
*Kidney disease 
*Tuberculosis 
*Other co morbid illnesses 
 
Personal history: 
*Smoking 
*Alcoholism 
 
General examination: 
Vitals: 
Pulse: 
Blood Pressure: 
Respiratory Rate: 
 
  
Systemic examination: 
CVS: 
RS: 
ABDOMEN: 
CNS: 
NIHSS scale: 
 
Investigations: 
 
CBC LIPID PROFILE 
RBC   TOTAL CHL  mg/dl 
TC DC   N                            L TGL  mg/dl 
            E B HDL   
HB   LDL   
ESR      
PLATELET     
     
RFT LFT 
Glucose  mg/dl Total bilirubin  mg/dl 
Urea  mg/dl Direct bilirubin  mg/dl 
Creatinine  mg/dl SGOT  U/l 
Na+  mEq/l SGPT  U/l 
K+  mEq/l ALP  U/l 
  Total protein  g/dl 
  Albumin  g/dl 
 
Vitamin D3: 
Random Blood glucose On admission: 
 
Chest X-ray: 
 
ECG: 
ECHO : 
 
MULTIMODAL CT (OR) MRI BRAIN DWI  
CAROTID AND VERTEBRAL DOPPLER: 
  
 
 
 
  
 
TURNITIN PLAGIARISM SCREEN SHOT 
 
  
 
  
PATIENT CONSENT FORM 
 
Study Title : “A STUDY ON VITAMIN-D LEVEL AND GLYCEMIC 
STATUS IN ACUTE ISCHEMIC STROKE AND THEIR 
IMPACT” 
 
Study Centre : Rajiv Gandhi Government General Hospital, Chennai. 
 
Name :  
 
Age/Sex :  
 
Identification Number :  
 
Patient may check (☑) these boxes 
The details of the study have been provided to me in writing and explained to me in my 
own language 
 ❏ 
I understand that my participation in the study is voluntary and that I am free to withdraw at 
any time without giving reason, without my legal rights being affected. 
 ❏ 
I understand that sponsor of the clinical study, others working on the sponsor’s behalf, the 
ethical committee and the regulatory authorities will not need my permission to look at 
my health records, both in respect of current study and any further research that may be 
conducted in relation to it, even if I withdraw from the study I agree to this access. 
However, I understand that my identity will not be revealed in any information released 
to third parties or published, unless as required under the law. I agree not to restrict the 
use of any data or results that arise from this study. 
❏ 
I agree to take part in the above study and to comply with the instructions given during the 
study and faithfully cooperate with the study team and to immediately inform the study 
staff if I suffer from any deterioration in my health or well being or any unexpected or 
unusual symptoms. 
 ❏ 
I hereby consent to participate in this study. 
 ❏ 
I hereby give permission to undergo complete clinical examination, diagnostic tests 
including hematological, biochemical tests and radiological tests. ❏ 
 
 
Signature/ Thumb impression                                  Signature of the investigator 
 
Patient’s name and address                                        Study Investigator’s name 
 
                                                                                 Dr. M. BALACHANDRAN 
INFORMATION SHEET 
We are conducting a study on “A STUDY ON VITAMIN-D LEVEL AND 
GLYCEMIC STATUS IN ACUTE ISCHEMIC STROKE AND THEIR IMPACT” 
among patients attending Rajiv Gandhi Government General Hospital, Chennai 
and for that your specimen may be valuable to us. 
 
The purpose of this study is to assess the “A STUDY ON VITAMIN-D 
LEVEL AND GLYCEMIC STATUS IN ACUTE ISCHEMIC STROKE AND THEIR 
IMPACT”. 
 
We are selecting certain cases and if you are found eligible, we may be 
using your specimen to perform extra tests and special studies which in any way 
do not affect your final report or management. 
 
The privacy of the patients in the research will be maintained throughout 
the study. In the event of any publication or presentation resulting from the 
research, no personally identifiable information will be shared. 
 
Taking part in this study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time; your decision will not result 
in any loss of benefits to which you are otherwise entitled. 
 
The results of the special study may be intimated to you at the end of the 
study period or during the study if anything is found abnormal which may aid in 
the management or treatment. 
 
 
 
Signature of Investigator Signature of Participant 
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1 65 M 98 7 15 24 9 A 
2 44 M 125 6 7 15 8 A 
3 48 M 117 11 12 20 8 A 
4 66 M 130 7 12 29 17 C 
5 60 M 455 28 38 68 30 B 
6 62 M 388 21 30 53 23 A 
7 55 M 103 10 12 26 14 A 
8 74 M 152 15 18 38 20 A 
9 48 M 130 17 18 36 18 C 
10 37 M 123 10 13 19 6 A 
11 74 M 413 24 20 48 28 B 
12 64 M 106 12 12 27 15 A 
13 68 M 108 13 16 30 14 A 
14 52 F 136 18 20 33 13 B 
15 58 F 135 8 6 12 6 A 
16 15 F 194 14 17 37 20 C 
17 38 F 96 11 11 25 14 A 
18 32 F 259 12 20 48 28 C 
19 75 F 176 14 18 40 22 A 
20 50 F 110 14 13 28 15 A 
21 73 F 114 9 16 24 8 A 
22 45 F 147 15 19 33 14 A 
23 40 F 166 16 16 29 13 A 
24 74 F 90 10 14 28 14 A 
25 59 F 137 14 27 46 19 A 
26 55 F 388 21 30 53 23 A 
27 85 F 231 18 28 43 25 B 
28 70 F 118 8 17 23 7 A 
29 18 F 122 8 18 28 10 A 
30 80 F 378 23 20 47 27 A 
31 60 F 113 9 10 18 8 B 
32 57 F 130 6 6 10 4 A 
33 45 F 132 9 18 36 18 A 
34 70 F 181 18 17 32 15 A 
35 45 M 174 17 18 39 21 A 
36 28 M 128 11 14 28 14 A 
37 40 M 126 12 11 18 7 B 
38 49 M 107 8 6 13 7 A 
39 45 M 199 20 17 37 20 C 
40 78 M 309 23 16 38 22 A 
41 64 M 186 19 15 34 19 A 
42 59 M 120 14 20 32 12 A 
43 84 M 124 13 14 28 14 B 
44 40 M 298 24 19 36 17 A 
45 84 M 210 17 22 43 19 A 
46 72 M 102 15 17 30 13 B 
47 58 M 217 20 25 47 22 A 
48 40 M 138 16 19 41 22 A 
49 52 M 102 14 16 28 12 A 
50 39 M 139 11 11 28 17 A 
 
VITAMIN D LEVELS 
A  - NORMAL 
B - INSUFFICIENCY 
C - DEFICIENCY 
